New Lonza site can now make Covid-19 vaccine ingredient
Swissmedic, the Swiss Agency for Therapeutic Products, has approved pharmaceutical company Lonza’s new site for making Moderna’s Covid-19 active substance.
This content was published on
1 minute
swissinfo.ch/sm
Español
es
Nuevo sitio de Lonza ya puede fabricar ingrediente de vacuna COVID-19
It issued the licence following a successful inspection of the production plant in Visp in southern Switzerland. At this newly approved site Lonza can manufacture, on behalf of Moderna, active substances for Covid-19 vaccines.
Swissmedic had already approved the first Swiss plant for the production of the substance in January 2021. At this newly approved site, called “Ibex® Solutions”, one production line is fully operational, and two more lines should be available soon.
Companies that manufacture or distribute medicinal or transplant products in Switzerland require an establishment licence proving that a company has the resources and processes needed to ensure and constantly monitor the quality of their products.
Lonza has a ten-year contract to supply ingredients to Moderna, including for up to one billion doses annually of Covid-19 vaccine.
More
More
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
Swiss factory rushes to prepare for Moderna Covid-19 vaccine
This content was published on
Workers are racing to set up production lines at the Lonza factory in Visp to be able to start making a vaccine for US firm Moderna later this year.
Switzerland to intensify border checks during sporting events
This content was published on
In the context of events including the European Football Championships and the summer Olympics, border security will be increased.
Integration of Credit Suisse into UBS now complete
This content was published on
Credit Suisse AG was formally integrated into UBS AG on Friday, with the former being subsequently deleted from Canton Zurich's commercial register.
This content was published on
The list of cities in the running as well as the requirements they need to meet have not been disclosed. A decision is to be made by the end of August.
UBS fined CHF50,000 for suspected money-laundering negligence
This content was published on
Switzerland’s finance ministry has fined UBS bank CHF50,000 after employees allegedly failed to report red flags of money laundering over several years.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.